Survodutide

• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
  PHASE3 RECRUITING Boehringer Ingelheim
• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
  PHASE3 RECRUITING Boehringer Ingelheim
• A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
  PHASE3 COMPLETED Boehringer Ingelheim
• A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight
  PHASE3 COMPLETED Boehringer Ingelheim
• A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease
  PHASE3 COMPLETED Boehringer Ingelheim

Showing 5 of 31 trials.

• A review of survodutide: a new dual acting agonist.
  Minerva Endocrinol (Torino) unknown
• Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Cirrhosis Clinical Trials: Lessons Learned and Future Directions.
  Drugs Review
• Operationalising disease modification in obesity trials: A blueprint based on the SYNCHRONIZE-1 survodutide study.
  Diabetes Obes Metab unknown
• Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial.
  JACC Heart Fail unknown
• Selective amylin receptor agonism: promise beyond incretins.
  Lancet unknown

Showing 5 of 20 papers by citation count.

FDA Data

Frequently Asked Questions